Business Context and Reporting Period
Company: ProQR Therapeutics N.V.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: January 2022 (Specifically January 4, 2022)
Context: The filing serves to distribute a press release regarding a clinical trial milestone for the Company's lead candidate, Sepofarsen.
Key Financial Metrics
This filing is a current report of a material event and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metric.
Material Changes
The material change reported is a clinical development milestone rather than a financial one:
- Clinical Trial Update: The last patient in the Phase 2/3 Illuminate Trial of Sepofarsen has completed their 12-month visit.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates by reference a press release titled "ProQR Announces Last Patient Has Completed 12 Month Visit in Phase 2/3 Illuminate Trial of Sepofarsen."
Guidance and Risks: The filing text does not provide specific forward-looking guidance, updated risk factors, or details on contingencies beyond the clinical milestone announcement.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for details on the clinical data outcomes from the 12-month visit.
- Review the Company's most recent Form 20-F or quarterly reports for current financial liquidity and cash runway, as this 6-K contains no financial data.
- Confirm the next expected regulatory or data readout dates for the Sepofarsen program based on the completion of the 12-month visit.